64Cu-labeled Lissamine rhodamine B: A promising PET radiotracer targeting tumor mitochondria

Molecular Pharmaceutics

Volumn 8, Issue 4, 2011, Pages 1198-1208

  Zhou, Yang ^a   Kim, Young Seung ^a   Yan, Xin ^a   Jacobson, Orit ^b   Chen, Xiaoyuan ^b   Liu, Shuang ^a  

^a PURDUE UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

64Cu PET radiotracers; mitochondrial potential; tumor imaging

Indexed keywords

2 [6 (DIETHYLAMINO) 3 (DIETHYLIMINIO) 3H XANTHEN 9 YL] 5 [N [2 [2 [4,7,10 TRIS(CARBOXYMETHYL) 1,4,7,10 TETRAAZACYCLODODECAN 1 YL]ACETAMIDO]ETHYL]SULFAMOYL]BENZENESULFONATE CU 64; CARBONYL CYANIDE CHLOROPHENYLHYDRAZONE; COPPER 64; FLUORESCENT DYE; LISSAMINE RHODAMINE B CU 64; RHODAMINE B; TRACER; UNCLASSIFIED DRUG; CARBONYLCYANIDE 4 CHLOROPHENYLHYDRAZONE; CARBONYLCYANIDE 4-CHLOROPHENYLHYDRAZONE; COPPER; DIAGNOSTIC AGENT; DRUG DERIVATIVE; LISSAMINE RHODAMINE B; RHODAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG PURITY; DRUG STABILITY; DRUG SYNTHESIS; DRUG UPTAKE; FEMALE; GLIOMA CELL; HEPATOBILIARY EXCRETION; HEPATOBILIARY PARAMETERS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; ISOTOPE LABELING; MICRO POSITRON EMISSION TOMOGRAPHY; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOLECULAR IMAGING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOCHEMISTRY; TUMOR CELL; TUMOR MITOCHONDRION; TUMOR XENOGRAFT; URINARY EXCRETION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; GLIOMA; METABOLISM; METHODOLOGY; NUDE MOUSE; SCINTISCANNING; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANIMALS; CARBONYL CYANIDE M-CHLOROPHENYL HYDRAZONE; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COPPER RADIOISOTOPES; FEMALE; GLIOMA; HUMANS; MICE; MICE, NUDE; MITOCHONDRIA; MOLECULAR STRUCTURE; POSITRON-EMISSION TOMOGRAPHY; RHODAMINES; TUMOR CELLS, CULTURED;

EID: 79961044837     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp200025m     Document Type: Article

References (61)

1. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer statistics, 2010 Ca-Cancer J. Clin. 2010, 60, 1-24
2. Kroemer, G.; Dallaporta, B.; Resche-Rigon, M. The mitochondrial death/life regulator in apoptosis and necrosis Annu. Rev. Physiol. 1998, 60, 619-642 (Pubitemid 28157889)
3. Modica-Napolitano, J. S.; Aprille, J. R. Delocalized lipophilic cations selectively target the mitochondria of carcinoma Cells Adv. Drug Delivery Rev. 2001, 49, 63-70 (Pubitemid 32493800)
4. Duchen, M. R. Mitochondria in health and disease: perspectives on a new mitochondrial biology Mol. Aspects Med. 2004, 25, 365-451 (Pubitemid 39070333)
5. Mannella, C. A. The relevance of mitochondrial membrane topology to mitochondrial function Biochim. Biophys. Acta 2006, 1762, 140-147 (Pubitemid 43006021)
6. Summerhayes, I. C.; Lampidis, T. J.; Bernal, S. D.; Nadakavukaren, J. J.; Nadakavukaren, K. K.; Shepard, E. L.; Chen, L. B. Unusual retention of Rhodamine 123 by mitochondria in muscle and carcinoma cells Proc. Natl. Acad. Sci. U.S.A. 1982, 77, 990-994
7. Modica-Napolitano, J. S.; Aprille, J. R. Basis for the selective cytotoxicity of Rhodamine 123 Cancer Res. 1987, 47, 4361-4365 (Pubitemid 17128145)
8. Davis, S.; Weiss, M. J.; Wong, J. R.; Lampidis, T. J.; Chen, L. B. Mitochondrial and plasma membrane potentials cause unusual accumulation and retention of Rhodamine 123 by human breast adenocarcinoma-derived MCF-7 cells J. Biol. Chem. 1985, 260, 13844-13850 (Pubitemid 16233244)
9. Dairkee, S. H.; Hackett, A. J. Differential retention of Rhodamine 123 by breast carcinoma and normal human mammary tissue Breast Cancer Res. Treat. 1991, 18, 57-61
10. Modica-Napolitano, J. S.; Singh, K. K. Mitochondria as targets for detection and treatment of Cancer Expert Rev. Mol. Med. 2002, 4, 1-19
11. Gottlieb, E.; Thompson, C. B. Targeting the mitochondria to enhance tumor suppression Methods Mol. Biol. 2003, 223, 543-554
12. Ross, M. F.; Kelso, G. F.; Blaikie, F. H.; James, A. M.; Cocheme, H. M.; Filipovska, A.; Da Ros, T.; Hurd, T. R.; Smith, R. A.; Murphy, M. P. Lipophilic triphenylphosphonium cations as tools in mitochondrial bioenergetics and free radical biology Biochemistry (Moscow) 2005, 70, 222-230 (Pubitemid 40512331)
13. Licha, K.; Olbrich, C. Optical imaging in drug discovery and diagnostic applications Adv. Drug Delivery Rev. 2005, 57, 1087-1108 (Pubitemid 40797571)
14. Jakobs, S. High resolution imaging of live mitochondria Biochim. Biophys. Acta 2006, 1763, 561-575 (Pubitemid 44015949)
15. Lichtshtein, D.; Kaback, H. R.; Blume, A. J. Use of a lipophilic cation for determination of membrane potential in neuroblastoma-glioma hybrid cell suspensions Proc. Natl. Acad. Sci. U.S.A. 1979, 76, 650-654 (Pubitemid 9135650)
16. Hockings, P. D.; Rogers, P. J. The Measurement of transmembrane electrical potential with lipophilic cations Biochim. Biophys. Acta 1996, 1282, 101-106 (Pubitemid 26189203)
17. Huang, S. G. Development of a high throughput screening assay for mitochondrial membrane potential in living cells J. Biomol. Screening 2002, 7, 383-389
18. Lefevre, C.; Kang, H. C.; Haugland, R. P.; Malekzadeh, N.; Arttamangkul, S.; Haugland, R. P. Texas Red-X and Rhodamine Red-X, new derivatives of sulforhodamine 101 and Lissamine Rhodamine B with improved labeling and fluorescence properties Bioconjugate Chem. 1996, 7, 482-489 (Pubitemid 26312139)
19. Lavis, L. D; Chao, T. Y.; Raines, R. T. Fluorogenic label for biomolecular imaging ACS Chem. Biol. 2006, 1, 252-260
20. Mao, C.; Kisaalita, W. S. Determination of resting membrane potential of individual neuroblastoma cells (IMR-32) using a potentiometric dye (TMRM) and confocal microscopy J. Fluoresc. 2004, 14, 739-743
21. Scaduto, R. C., Jr.; Grotyohann, L. W. Measurement of mitochondrial membrane potential using fluorescent rhodamine derivatives Biophys. J. 1999, 76, 469-477 (Pubitemid 29202474)
22. Hama, Y.; Urano, Y.; Koyama, Y.; Kamiya, M.; Bernardo, M.; Paik, R. S.; Shin, I. S.; Paik, C. H.; Choyke, P. L.; Kobayashi, H. A target cell-specific activatable fluorescence probe for in vivo molecular imaging of cancer based on a self-quenched Avidin-Rhodamine conjugate Cancer Res. 2007, 67, 2791-2799 (Pubitemid 46548968)
23. Glunde, K.; Foss, C. A.; Takagi, T.; Wildes, F.; Bhujwalla, Z. M. Synthesis of 6′- O -Lissamine-Rhodamine B-glucosamine as a novel probe for fluorescence imaging of lysosomes in breast tumors Bioconjugate Chem. 2005, 16, 843-851 (Pubitemid 41026171)
24. Longmire, M. R.; Ogawa, M.; Hama, Y.; Kosaka, N.; Regino, C. A.; Choyke, P. L.; Kobayashi, H. Determination of optimal rhodamine fluorophore for in vivo optical imaging Bioconjugate Chem. 2008, 19, 1735-1742
25. Yova, D.; Atlamazoglou, V.; Kavantzas, N.; Loukas, S. Development of a fluorescence-based imaging system for colon cancer diagnosis using two novel rhodamine derivatives Lasers Med. Sci. 2000, 15, 140-147 (Pubitemid 30209644)
26. Heinrich, T. K.; Gottumukkala, V.; Snay, E.; Dunning, P.; Fahey, F. H.; Ted Treves, S.; Packard, A. B. Synthesis of fluorine-18 labeled Rhodamine B: a potential PET myocardial perfusion imaging agent Appl. Radiat. Isot. 2010, 68, 96-100
27. 18F]fluoroethylrhodamine B, a potential PET myocardial perfusion agent Nucl. Med. Biol. 2010, 37, 365-370
28. 123I]Iodo-1- penten-5-Yl]triphenylphosphonium iodide: convenient preparation of a potentially useful myocardial perfusion agent J. Med. Chem. 1984, 27, 978-981 (Pubitemid 14057356)
29. Srivastava, P. C.; Hay, H. G.; Knapp, F. F., Jr. Effects of alkyl and aryl substitution on the myocardial specificity of radioiodinated phosphonium, arsonium, and ammonium cations J. Med. Chem. 1985, 28, 901-904 (Pubitemid 15012497)
30. 3H-tetraphenylphosphonium by nerve system tumor cells J. Neurosurg. 1991, 74, 116-122
31. 11C] methyl triphenyl phosphonium: measurements of the extraction fraction and myocardial uptake J. Nucl. Biol. Med. 1994, 38, 521-526 (Pubitemid 24344266)
32. 11C]TPMP in canine brain tumor: a PET study J. Nucl. Med. 1999, 40, 1180-1185 (Pubitemid 29315511)
33. 99mTc-MIBI J. Nucl. Med. 2002, 43, 234-238 (Pubitemid 34151048)
34. 18F]fluorobenzyl triphenylphosphonium in dog myocardium J. Nucl. Med. 2006, 47, 1359-1366 (Pubitemid 47544892)
35. Min, J. J.; Biswal, S.; Deroose, C.; Gambhir, S. S. Tetraphenylphosphonium as a novel molecular probe for imaging tumors J. Nucl. Med. 2004, 45, 636-643 (Pubitemid 47618595)
36. Cheng, Z.; Winant, R. C.; Gambhir, S. S. A new strategy to screen molecular imaging probe uptake in cell culture without radiolabeling using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry J. Nucl. Med. 2005, 46, 878-886
37. 18F]fluorophenyl) triphenylphosphonium ion. A potential myocardial blood flow agent for PET. Mol. Imaging Biol. 2010, available online.
38. Anderson, C. J.; Green, M. A.; Fujibayashi, Y. Chemistry of copper radionuclides and radiopharmaceutical products. In Handbook of Radiopharmaceuticals: Radiochemistry and Applications; Welch, M. J.; Redvanly, C., Eds.; John Wiley & Sons, Ltd.: 2003; pp 401-422.
39. Blower, P. J.; Lewis, J. S.; Zweit, J. Copper radionuclides and radiopharmaceuticals in nuclear medicine Nucl. Med. Biol. 1996, 23, 957-980 (Pubitemid 27050682)
40. Smith, S. V. Molecular imaging with copper-64 J. Inorg. Biochem. 2004, 98, 1874-1901 (Pubitemid 39456427)
41. Liu, S. The role of coordination chemistry in the development of target-specific radiopharmaceuticals Chem. Soc. Rev. 2004, 33, 445-461 (Pubitemid 39461952)
42. Reichert, D. E.; Lewis, J. S.; Anderson, C. J. Metal complexes as diagnostic tools Coord. Chem. Rev. 1999, 184, 3-66
43. Anderson, C. J.; Welch, M. J. Radiometal-labeled agents (Non-Technetium) for diagnostic imaging Chem. Rev. 1999, 99, 2219-2234
44. Liu, S. Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides Adv. Drug Delivery Rev. 2008, 60, 1347-1370
45. 64Cu(DO3A-xy-TPEP) as a potential PET radiotracer for monitoring tumor multidrug resistance Bioconjugate Chem. 2009, 20, 790-798
46. 64Cu-Labeled triphenylphosphonium and triphenylarsonium cations as highly tumor-selective imaging agents J. Med. Chem. 2007, 50, 5057-5069 (Pubitemid 47585703)
47. 64Cu-labeled triphenylphosphonium cations J. Med. Chem. 2008, 51, 2971-2984 (Pubitemid 351706025)
48. 64Cu-Labeled 2-(diphenylphosphoryl) ethyldiphenylphosphonium cations as highly selective tumor imaging agents: effects of linkers and chelates on radiotracer biodistribution characteristics Bioconjugate Chem. 2008, 19, 2008-2022
49. de Graaf, A. O.; van den Heuvel, L. P.; Dijkman, H. B.; de Abreu, R. A.; Birkenkamp, K. U.; de Witte, T.; van der Reijden, B. A.; Smeitink, J. A.; Jansen, J. H. Bcl-2 prevents loss of mitochondria in CCCP-induced apoptosis Exp. Cell Res. 2004, 299, 533-540 (Pubitemid 39179817)
50. Horton, K. L.; Stewart, K. M.; Fonseca, S. B.; Guo, Q.; Kelley, S. O. Mitochondria-penetrating peptides Chem. Biol. 2008, 15, 375-382 (Pubitemid 351508434)
51. 64Cu-labeled dimeric RGD-peptides Mol. Imaging Biol. 2004, 6, 350-359 (Pubitemid 39243068)
52. 64Cu-labeled tetrameric RGD peptide J. Nucl. Med. 2005, 46, 1707-1718 (Pubitemid 46211595)
53. 4 linkers Bioconjugate Chem. 2009, 20, 750-759
54. 4 linkers Mol. Pharmaceutics 2009, 6, 231-245
55. 99mTc-labeled cyclic Arginine-Glycine-Aspartic (RGD) dimers with triglycine linkers J. Med. Chem. 2008, 51, 7980-7990
56. Boswell, C. A.; Sun, X.; Niu, W.; Weisman, G. R.; Wong, E. H.; Rheingold, A. L.; Anderson, C. J. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes J. Med. Chem. 2004, 47, 1465-1474 (Pubitemid 38327472)
57. Boswell, C. A.; McQuade, P.; Weisman, G. R.; Wong, E. H.; Anderson, C. J. Optimization of labeling and metabolite analysis of copper-64-labeled azamacrocyclic chelators by radio-LC-MS Nucl. Med. Biol. 2005, 32, 29-38 (Pubitemid 40187379)
58. Sprague, J. E.; Peng, Y.; Fiamengo, A. L.; Woodin, K. S.; Southwick, E. A.; Wiseman, G. R.; Wong, E. H.; Golden, J. A.; Rheingold, A. L.; Anderson, C. J. Synthesis, characterization and in vivo studies of Cu(II)-64-labeled cross-bridged tetraazamacrocycle-amide complexes as models of peptide conjugate imaging agents J. Med. Chem. 2007, 50, 2527-2535 (Pubitemid 46799265)
59. 18F-fluorodeoxyglucose J. Neurooncol. 2000, 46, 63-70 (Pubitemid 30352613)
60. Filippi, L.; Santoni, R.; Manni, C.; Danieli, R.; Floris, R.; Schillaci, O. Imaging primary brain tumors by single-photon emission computed tomography (SPECT) with technetium-99m Sestamibi (MIBI) and Tetrofosmin Curr. Med. Imaging Rev. 2005, 1, 61-66
61. Le Jeune, N.; Perek, N.; Denover, D.; Dubois, F. Influence of gluthione depletion on plasma membrane cholesterol esterification and on Tc-99m-Sestamibi and Tc-99m-Tetrofosmin uptakes: a comparative study in sensitive U87MG and multidrug-resistant MRP1 human glioma cells Cancer Biother. Radiopharm. 2004, 19, 411-421 (Pubitemid 39281333)